ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naive MSM from 2011 to 2013 in Beijing, China.
 PMID: 25510523       2014       BMC infectious diseases
Table: Q58E


  Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
 PMID: 25575025       2014       Retrovirology
Table: Q58E


  Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina.
 PMID: 24093951       2013       Journal of the International AIDS Society
Method: Sequences were analyzed to identify mutations associated with reduced susceptibility to protease and RT inhibitors, as reported by the International AIDS Society-USA in 2010: RT-M41L, A62V, K65R, D67N, 69 insert, K70R, L74V,V75I, F77L, L100I, K101P, K103N, V106A, V106M, V108I, Y115F, F116Y,


  Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul.
 PMID: 23296905       2013       Medical microbiology and immunology
Abstract: In these patients, the nucleoside reverse transcriptase inhibitor (NRTI)-associated resistance mutations M41L, T215C, V75I, T69N, the non-NRTI associated mutations V106I, E138A, K103N and the protease inhibitor associated mutations Q58E and V82I were detected.


  "Description of the L76V resistance protease mutation in HIV-1 B and ""non-B"" subtypes."
 PMID: 23349869       2013       PloS one
Method: In our study, samples with at least one of the major PI RAM of the IAS-USA list as follows: D30N, V32I, M46I/L, I47A/V, G48V, I50L/V, I54L/M, Q58E, T74P, L76V, V82A/F/L/T/S, N83D, I84V, N88S, L90M were considered as PI-resistant issued from PI-experienced patients.
Result: Among subtype B samples, the major


  Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
 PMID: 23590295       2013       Journal of medicinal chemistry
Introduction: Recently, we characterized a clinically derived HIV-1 protease (PR20) bearing 20 mutations [Q7K, L10F, I13V, I15V, D30N, V32I, L33F, E35D, M36I, S37N, I47V, I54L, Q58E, I62V, L63P, A71V, I84V, N88D, L89T and L90M] and extremely resist


  Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.
 PMID: 24009694       2013       PloS one
Table: Q58E


  Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
 PMID: 21755502       2011       Journal of medical virology
Abstract: L90M, I54V and Q58E were associated with L76V in a multivariate analysis (P < 0.0001, P = 0.002, and P = 0.008, respectively).
Abstract: In univariate analyses, of the mutations found in _10% of patients, L89M and Q58E were more prevalent in viruses L76V positive than L76V negative (L89M, 42% vs. 0%, P = 0.0007; Q58E, 50% vs. 25%, P = 0.1).
Abstract: One contains the L76V and Q58E mutations and the other contains the L90M and I54V mutations.


  Drug resistance mutations in patients infected with HIV-2 living in Spain.
 PMID: 21558334       2011       The Journal of antimicrobial chemotherapy
Abstract: No major mutations associated with drug resistance in HIV-1 were recognized in 29 PR, 20 RT and 5 INT sequences from antiretroviral-naive HIV-2 individuals, although natural polymorphisms with potential effects on susceptibility to PR inhibitors were recognized at 10 positions (L10V/I, V32I, M36I, M46I, I47V, Q58E, A71V/I, G73A, V82I and L89I/V) and for nucleoside reverse transcriptase inhibitors at three positions (T69N, V75I


  Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.
 PMID: 20532178       2010       PloS one
Table: Q58E



Browser Board

 Co-occurred Entities




   Filtrator